Pharmaceuticals
| Oncology | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
|
|
||||||||||||||||
|
|
||||||||||||||||
KDev Oncology AB (GliGene) |
|
|||||||||||||||
| Infections and Wound Healing | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pergamum AB (DPK-060, external otitis) |
|
|||||||||||||||
Pergamum AB (DPK-060, infected eczema) |
|
|||||||||||||||
Pergamum AB (PXL01) |
|
|||||||||||||||
Dilaforette AB (Sevuparin, malaria) |
|
|||||||||||||||
Pergamum AB (LL-37) |
|
|||||||||||||||
|
|
||||||||||||||||
Pergamum AB (PXL181) |
|
|||||||||||||||
| Women's Health | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
|
|
||||||||||||||||
|
|
||||||||||||||||
| Cardiovascular | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Athera Biotechnologies AB (Annexin A5) |
|
|||||||||||||||
Athera Biotechnologies AB (PC-mAb) |
|
|||||||||||||||
Dilaforette AB (Sevuparin, SCD) |
|
|||||||||||||||
| Ophthalmology | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
| CNS | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
|
|
||||||||||||||||
| Inflammation | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
Technology
| Implants | Concept Development | Prototype | Development | Product | Sales | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
|
|
||||||||||
| Diagnostics | Concept Development | Prototype | Development | Product | Sales | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Athera Biotechnologies AB (lgM anti-PC (CVDefine kit)) |
|
|||||||||
|
|
||||||||||
| Pharmaceutical Formulation | Concept Development | Prototype | Development | Product | Sales | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
|
|
||||||||||
|
|
||||||||||
| Medical Equipment | Concept Development | Prototype | Development | Product | Sales | |||||
|---|---|---|---|---|---|---|---|---|---|---|
NeoDynamics AB (Fourier/AS) |
|
|||||||||
NeoDynamics AB (Therapy/PRFA, Anti-Meta) |
|
|||||||||
Passive/Financial Investments
| Pharmaceutical | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pergamum AB (Laurantis Pharma Oy) (cis-UCA dermatology) |
|
|||||||||||||||
|
|
||||||||||||||||
|
|
||||||||||||||||
Pergamum AB (Laurantis Pharma Oy) (cis-UCA oncology) |
|
|||||||||||||||
Pergamum AB (Laurantis Pharma Oy) (ad-VEGF-C) |
|
|||||||||||||||
|
|
||||||||||||||||
Solid colored area = completed phase Shaded colored area = ongoing phase
